J. Andrew Orr-Skirvin

PharmD, RPh, BCOP

Chair, Department of Pharmacy and Health Systems Sciences; Director of Pharmaceutical Industry Fellowship Program; Clinical Professor

Pharmacy and Health Systems Science


Research Interests

Supportive care for the cancer patient including: pain management, nausea & vomiting, neutropenic fever, long term complications, growth factor support, etc.

Publications

Skirvin JA, Patel P. Update on FDA approvals and selected investigational agents. Newsletter, Hematology/Oncology Pharmacy Association, HOPA News, Winter 2006;5-7.

Skirvin JA. Chapter 44, Thrombocytopenia. In Tisdale JE, Miller, DA, editors. Drug-Induced Diseases, prevention, detection, and management. American Society of Health-System Pharmacists. Bethesda, MD; 2005:649-60.

Skirvin JA, Lichtman SM: Pharmacokinetic considerations of oral chemotherapy in elderly cancer patients. Drugs Aging 2002;19:25-42.

Skirvin JA. Melanoma: current detection and management strategies. US Pharmacist Health-System edition 2001;Supplement September:17-28.

Skirvin JA, Vemulapalli S, Lichtman SM: Pharmacology of antineoplastic agents in older cancer patients. Oncology Spectrum 2001;2:404-13.

Skirvin JA, Gorowski E, D’Olimpio JT. Promoting in-patient pain management at a university hospital with comprehensive needs assessment. Proceedings of ASCO 2001;20:304b.

Lichtman S, Skirvin JA. Pharmacology of antineoplastic agents in older cancer patients. Oncology 2000;14:1743-55

Skirvin JA, D’Olimpio JT, Gorowski E. Pain assessment survey of adult oncology admissions: a performance improvement project (Abstract). Proceedings of ASCO 2000,19:640a.

Skirvin JA. Topotecan. CancerRX in Cancer Therapeutics 1999;2:121-5.

Stirling A, Kao E, Skirvin J, Hirsch B. Impact of pharmacist-run aminoglycoside once daily program in a tertiary teaching institution (Abstract). Pharmacotherapy 1999;19:517.

Skirvin JA, Lichtman SM, Negri A, et al. Pharmacist intervention program monitoring filgrastim use in hospitalized patients (Abstract 2252). Proceedings of ASCO 1999;18:583a.

Taibbi R, Kao E, Skirvin JA, et al. Development of an performance improvement program to increase the safety of chemotherapy administration (Abstract 2343). Proceedings of ASCO 1999;18:607a.

Stirling A, Kao E, Skirvin J, Hirsch B. Impact of pharmacist-run aminoglycoside once daily program in a tertiary teaching institution (Abstract). Pharmacotherapy 1999;19:517.

Castanheira D, Marzella M, Skirvin JA. Administration of filgrastim in two patients with drug-induced agranulocytosis. Pharmacotherapy 1998;18:1347-51.

Skirvin JA, Relias V. Topoisomerase Inhibitors: 2. Irinotecan. J Oncol Pharm Practice 1998;4:103-16.

Skirvin JA, Valley AW, Relias V, Morris AK. 6-Mercaptopurine hepatoxicity during acute lymphocytic leukemia maintenance therapy. J Oncol Pharm Practice 1998;4:117-20.

Skirvin JA, Brocavich JM. IV Immunoglobulin Therapy in Immunosuppressed Patients. US Pharmacist health-system edition 1998;23:HS-37-48.

Community Service

Service to cancer patients through my clinical practice site.